Loading...

SGMO SANGAMO THERAPEUTICS INC Operational Disruptions 8-K Filing

SNGM

SGM

SANGAMO THERAPEUTICS INC

(SGMO)

2024 8-K

Financial Results Announce

Stock Offering Announcement

Sangamo's Clinical Data

Management Changes

Financial Results Announced

Compliance Extension Granted

Management Changes

Management Change

Clinical Data Update

Financial Statements

Product Expansion

Equity Offerings

Equity Offerings

Delisting due to Non-Compli...

Financial Results

Clinical Data Update

Collaboration Termination

Stock Increase Validated

Financial Results

Share Increase Approval

Financial Results Announcement

Announcement of Positive Re...

Amendment and Restatement o...

Financial Results Announcement

Securities Purchase Agreement

Financial Results Announcement

Clinical Data Announcement

Departure of Directors and ...

Data Presentation

Gene Therapy Presentation

Earnings Reports

Financial Results Announcement

Amendment and Restatement A...

Financial Results and Restr...

Termination of Collaboratio...

Transfer of Deposits

FDIC Press Release

Amendment to Sales Agreement

Public Offering Decision

Financial Results Announcement

External Links:

Sangamo Therapeutics announced updated preliminary clinical data from its Phase 1/2 STAAR study on its gene therapy product candidate for Fabry disease, with positive results in terms of safety and efficacy.

AI Assistant

SANGAMO THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.